fda rules on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified What Changed? The FDA's Clarification
Description
This delicate balance between access and affordability is critical to watch as the market evolves
The prevalence of type 2 diabetes (T2D) is increasing worldwide, with many patients developing long-term complications that affect their cardiovascular, urin...
Mounjaro is the brand name for tirzepatide
Rumors about semaglutide bans circulate online, but compounded versions from licensed 503A pharmacies remain legal and accessible
